Loading clinical trials...
Loading clinical trials...
A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers
Conditions
Interventions
ZW49
Locations
16
United States
City of Hope
Duarte, California, United States
Moffitt Cancer Center
Tampa, Florida, United States
University of Chicago Medicine
Chicago, Illinois, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Start Date
April 15, 2019
Primary Completion Date
September 27, 2024
Completion Date
October 8, 2024
Last Updated
January 29, 2025
Lead Sponsor
Zymeworks BC Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions